Tyra Biosciences Inc (TYRA NASDAQ) stock market data APIs
$13.64
-0.01(-0.1%)
as of February 4, 2025
Tyra Biosciences Inc Financial Data Overview
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Prev. Close
13.5
Open
13.64
High
13.99
Low
13.5
52 wk Range
13.2705-29.6
Market Cap
691 M
Shares Outstanding
50 603 K
Revenue
0
EPS
-0.41
Beta
1.078
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tyra Biosciences Inc data using free add-ons & libraries
Get Tyra Biosciences Inc Fundamental Data
Tyra Biosciences Inc Fundamental data includes:
- Net Revenue: 0
- EBITDA: -99 594 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-08
- EPS/Forecast: -0.392
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tyra Biosciences Inc News
New
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug BofA Securities has upgraded Tyra Biosciences (NASDAQ:TYRA), a clinical-stag...
16 Most Promising Long-Term Stocks According to Analysts
In this piece, we will take a look at the 16 most promising long-term stocks according to analysts. If you want to skip our overview of long term investing, then you can take a look at 5 Most Promisin...
BOXER CAPITAL, LLC Boosts Stake in Mirati Therapeutics Inc
BOXER CAPITAL, LLC, a San Diego-based investment firm, recently increased its holdings in Mirati Therapeutics Inc (NASDAQ:MRTX) on August 11, 2023. This article aims to provide an in-depth analysis of...
Boxer Capital, Llc Buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, ...
Investment company Boxer Capital, Llc (Current Portfolio) buys Tyra Biosciences Inc, Tango Therapeutics Inc, Blueprint Medicines Corp, Fulcrum Therapeutics Inc, Turning Point Therapeutics Inc, sells S...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
